Author's response to reviews Title:A phase-II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer Authors:
نویسندگان
چکیده
Kazuhisa Yamaguchi ([email protected]) Hiroya Taniguchi ([email protected]) Azusa Komori ([email protected]) Yukiya Narita ([email protected]) Sohei Nitta ([email protected]) Motoo Nomura ([email protected]) Shigenori Kadowaki ([email protected]) Daisuke Takahari ([email protected]) Takashi Ura ([email protected]) Masashi Andoh ([email protected]) Kei Muro ([email protected]) Keita Mori ([email protected]) Yoshinori Igarashi ([email protected])
منابع مشابه
Targeting vascular endothelial growth factor in colorectal cancer.
Recent trials have established the IFL combination (fluorouracil [5-FU], leucovorin, and irinotecan [CPT-11, Camptosar]) as a new standard first-line therapy for patients with metastatic colorectal cancer. Median survival for such patients treated with IFL still ranges from approximately 14 to 18 months, however, underscoring the need for new agents with novel mechanisms of action. Angiogenesis...
متن کاملSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT
27(5): 672–680. 19. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842–1847. 20. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observationa...
متن کاملA Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
OBJECTIVES Protracted low-dose infusion of irinotecan has been suggested to enhance antitumor activity. A phase II study was conducted to evaluate the safety and efficacy of oral S-1 combined with 24-hour infusion of irinotecan and intravenous bevacizumab for metastatic colorectal cancer (MCRC). METHODS The subjects were 79 patients with MCRC; 57 were chemotherapy naïve. Irinotecan (125 mg/m(...
متن کاملA phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
BACKGROUND This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with histologically confirmed mCRC (adenocarcinoma), an Eastern Cooperativ...
متن کاملSIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
TAKE-AWAY POINTS This multicenter international study randomized patients with metastatic colorectal cancer (mCRC) between first-line systemic chemotherapy alone and first-line systemic chemotherapy combined with yttrium-90 (Y-90) resin microspheres. Eligible patients with nonresectable liver-only or liver-dominant mCRC and no prior systemic chemotherapy were randomized 1:1 between both arms. T...
متن کامل